208 related articles for article (PubMed ID: 8334935)
1. [Soluble interleukin 2 receptor (sIL-2R) in patients with esophageal carcinoma].
Duan ZF
Zhonghua Zhong Liu Za Zhi; 1993 Jan; 15(1):17-9. PubMed ID: 8334935
[TBL] [Abstract][Full Text] [Related]
2. [The level of soluble interleukin 2 receptor in esophageal carcinoma patients before and after radiotherapy].
Liu X; An H; Jiang Y
Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):97-9. PubMed ID: 7656815
[TBL] [Abstract][Full Text] [Related]
3. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
4. Impaired CD25 expression and soluble CD25-IL-2R alpha receptor release by anti-CD3 stimulated peripheral blood mononuclear cells in Hodgkin's disease patients.
Frydecka I; Mazur G
Arch Immunol Ther Exp (Warsz); 1996; 44(2-3):127-30. PubMed ID: 8915517
[TBL] [Abstract][Full Text] [Related]
5. Soluble interleukin-2 receptor in serum of patients with esophageal carcinoma.
Jabłońska E; Kozłowski M; Pietruska Z; Furman M
Neoplasma; 1994; 41(6):315-8. PubMed ID: 7870214
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
7. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition.
Symons JA; Wood NC; Di Giovine FS; Duff GW
J Immunol; 1988 Oct; 141(8):2612-8. PubMed ID: 3262665
[TBL] [Abstract][Full Text] [Related]
8. Correlation between density of beta 2-adrenergic receptors on peripheral blood mononuclear cells and serum levels of soluble interleukin-2 receptors in patients with chronic inflammatory diseases.
Krause A; Henrich A; Beckh KH; Von Wichert P; Baerwald C
Eur J Clin Invest; 1992 Oct; 22 Suppl 1():47-51. PubMed ID: 1333967
[TBL] [Abstract][Full Text] [Related]
9. Hemodialysis related interleukin-2 receptor release by peripheral blood mononuclear cells.
Memoli B; Libetta C; De Nicola L; Rampino T; Capuano A; Guida B; Andreucci VE
ASAIO J; 1996; 42(1):60-3. PubMed ID: 8808460
[TBL] [Abstract][Full Text] [Related]
10. [Serum soluble IL-2 receptor level in patients with sarcoidosis].
Ina Y; Takada K; Noda M; Satou T; Hashiba H; Miyachi A; Ito S; Iijima N; Yamamoto M
Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Mar; 29(3):316-21. PubMed ID: 2067152
[TBL] [Abstract][Full Text] [Related]
11. Gamma-interferon and soluble interleukin 2 receptor in tuberculous pleural effusion.
Kim YK; Lee SY; Kwon SS; Kim KH; Moon HS; Song JS; Park SH
Lung; 2001; 179(3):175-84. PubMed ID: 11891607
[TBL] [Abstract][Full Text] [Related]
12. Effect of luteinizing hormone alpha-subunit on IL-2 and sIL-2R in vitro secretions from human peripheral blood mononuclear cells.
Komorowski J; Gradowski G; Stepień H
Cytobios; 1997; 89(356):31-7. PubMed ID: 9297814
[TBL] [Abstract][Full Text] [Related]
13. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
14. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice.
Wasik MA; Sioutos N; Tuttle M; Butmarc JR; Kaplan WD; Kadin ME
Am J Pathol; 1994 May; 144(5):1089-97. PubMed ID: 8178932
[TBL] [Abstract][Full Text] [Related]
15. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
16. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
Macciò A; Lai P; Santona MC; Pagliara L; Melis GB; Mantovani G
Gynecol Oncol; 1998 Jun; 69(3):248-52. PubMed ID: 9648596
[TBL] [Abstract][Full Text] [Related]
17. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
18. [Changes in serum IL-2 and sIL-2R levels in patients with primary hepatic carcinoma before and after treatment and their clinical significance].
Wang M; Feng Y; Zhou X
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):33-5. PubMed ID: 7656784
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of soluble interleukin-2 receptor in patients with ANCA-associated vasculitis.
Arranz O; Ara J; Rodríguez R; Saurina A; Mirapeix E; Darnell A
J Nephrol; 2000; 13(1):59-64. PubMed ID: 10720216
[TBL] [Abstract][Full Text] [Related]
20. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
